

The story behind moderna's IPO

The biggest US biotech IPO to date

Data sourced from the PitchBook Platform

NASDAQ: MRNA	\$23 price per share	26.3M shares for sale	\$604M to be raised from IPO
---------------------	--------------------------------	---------------------------------	--

Revenue: \$99.65M FY 2018 ↓12.5% YoY	Net loss: \$243.31M FY 2018 ↑11.6% YoY	Industry: Biotechnology	 8 years to IPO
--	--	-----------------------------------	--

\$1.7 billion total VC funding to date	Location:  MA, USA	 700 employees (as of December 2018)
--	--	---






moderna's Executive Committee

 Stéphane Bancel CEO	 Stephen Hoge M.D., President	 Juan Andres Chief Technology Officer and Quality Officer
 Marcello Damiani Chief Digital Officer	 Lorence Kim M.D., Chief Financial Officer	 Tal Zaks M.D., Ph.D., Chief Medical Officer

Shareholders + percent of ownership

Flagship Pioneering:	19.5%
Noubar B. Afeyan:	19.5%
Stéphane Bancel CEO:	10.0%
AstraZeneca:	8.4%
Robert Langer President:	3.9%

How moderna compares to other 2018 US biotech IPOs

 moderna Valuation: \$7.6B	 Solid Biosciences Valuation: \$546.4M	 ARMO Biosciences Valuation: \$497.7M
	 Homology Medicines Valuation: \$577.3M	 Allogene Therapeutics Valuation: \$2.2B

Refers to shares beneficially owned before the offering

